The latest announcement is out from Spectral Medical ( (TSE:EDT) ).
Spectral Medical Inc. has announced an update on its Tigris trial, a Phase 3 study evaluating the use of Polymyxin B Hemoperfusion (PMX) for treating endotoxemia and septic shock. With 152 patients enrolled, the trial is nearing its target of 150 evaluable patients, expected to be reached by the end of March 2025. The completion of this trial is crucial for PMX’s regulatory review, particularly concerning safety and secondary analyses, which could significantly impact Spectral’s market positioning and stakeholder interests.
More about Spectral Medical
Spectral Medical Inc. is a late-stage theranostic company focused on advancing therapeutic options for sepsis and septic shock. The company is seeking U.S. FDA approval for its product Toraymyxin (PMX), a therapeutic hemoperfusion device designed to remove endotoxin from the bloodstream. PMX is already approved for use in Japan and Europe and has been used on over 340,000 patients. Spectral holds exclusive development and commercial rights for PMX in the U.S. and Canada.
YTD Price Performance: 27.37%
Average Trading Volume: 13,705
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $144M
See more data about EDT stock on TipRanks’ Stock Analysis page.